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Abstract : Psoriasis is a chronic immune-mediated disease in which the interleukin 
（IL）-23/IL-17 axis plays a key role in the inflammatory cascade.  We recently 
reported that co-expression of CCR6 and melanoma cell adhesion molecule 
（MCAM） in effector memory CD4 T cells （TEM） of peripheral blood might be 
a useful marker for T helper （Th） 17 cells.  In this study, we monitored changes 
in TEM expressing CCR6 and MCAM using the Psoriasis Area and Severity Index 
（PASI） score during anti-tumor necrosis factor （TNF） therapy.  We also studied 
CCR6＋ MCAM＋ Th17 cells histologically in skin biopsy samples from psoriasis 
patients.  In psoriasis patients treated with anti-TNF therapy, the PASI score and 
the percentage of CCR6＋ MCAM＋ TEM cells in the blood changed almost in 
parallel.  In immunohistochemical analyses, the proportions of IL-17＋ T cells and 
MCAM＋ T cells in the lesional skin of severely psoriatic patients were signicantly 
higher than in mildly psoriatic patients （P ＜ 0.05）, and the number of IL17＋ T 
cells correlated with the PASI score （r＝ 0.400, P＜ 0.05）.  Taken together, these 
results indicate that CCR6＋ MCAM＋ Th17 cells in peripheral blood and lesional 
skin might play an important role in the pathology of psoriasis.
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Introduction
　Psoriasis is a chronic immune-mediated disease that affects 2-4％ of the general population 
worldwide1-3).  Over the past two decades, increased research into the physiopathology of psoria-
sis has resulted in novel therapeutic options4-6).  T helper （Th）17 cells have been shown to play a 
key role in the inammatory cascade central to the disease, via the so-called interleukin （IL）-23 /
IL-17 axis7-8).  Accordingly, psoriasis is sensitive to biological agents targeting IL-17 and IL-23 9-11).
　Effector memory CD4 T cells （TEM） migrate into inamed tissues, produce various cytokines, 
and aggravate psoriasis12）.  In addition, Th17 cells, a subset of CD4＋ T helper cells, characteristi-
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cally secrete cytokines such as IL-17 and play important roles in the pathogenesis of several 
inflammatory and autoimmune diseases13）.  Although several cell surface markers for human 
Th17 cells have been reported （including CCR6, MCAM, and CD161 ）14-16), none has demonstrat-
ed practical utility in determining the severity of psoriasis.  For example, although Th17 expresses 
CCR6 13）, this is not a reliable clinical marker of psoriasis.
　The CD146 / melanoma cell adhesion molecule （MCAM or MUC18 ） belongs to the immuno-
globulin superfamily, and has been identied initially as a useful marker of melanoma progres-
sion and metastasis17）.  In normal adult tissues, MCAM is expressed primarily by vascular endo-
thelium and smooth muscle, where it plays roles in cellular adhesion.  MCAM was also reported 
to be a marker of activated T cell groups that are enriched in TEM18）, and to aid the migration 
of Th17 cells into the central nervous system of patients with multiple sclerosis14）.  Previously, 
we reported that CCR6＋ MCAM＋ TEM produced more IL-17 than other TEM subsets in a study 
designed to clarify whether the CCR6＋ MCAM＋ phenotype could identify pathogenic Th17 cells 
in patients with psoriasis19）.  In the present study, CCR6＋ MCAM＋ TEM, that enriches Th17 cells 
in both peripheral blood and CCR6＋ MCAM＋ IL-17＋ CD4 T cells in lesional skin, seemed to 
correlate with psoriatic disease severity.  We also discuss the pathogenic roles played by these 
markers in the Th17 cell-mediated responses to disease.
Materials and methods
Patients
Blood samples from healthy controls and psoriatic patients
　We studied two naïve patients with psoriasis vulgaris who were treated with anti-TNF therapy 
（infliximab） at Showa University Hospital.  Before and after treatment, we collected blood 
samples and determined the Psoriasis Area and Severity Index （PASI） scores to evaluate the 
severity of psoriasis.  
　
Skin samples from psoriatic patients
　We obtained skin samples from 34 patients （21 males, 13 females, aged 21-87 years ; mean 
age, 59.2 years） newly diagnosed with psoriasis vulgaris in the Department of Dermatology at 
Showa University Hospital from 2010 to 2014.  Medical records were also reviewed to extract 
clinical information and laboratory data.  We divided the patients into two groups : those with 
mild （PASI＜ 12） and severe （PASI ≥ 12） disease.  The mean PASI score was 11.7 ; the mean 
scores of the mild and severe groups were 4.97 ± 0.60 （mean ± SEM） and 19.3 ± 1.07, respectively.  
　Written informed consent to participate in the study was obtained from all patients.  The Eth-
ics Committee of Showa University School of Medicine approved this study.
　
Flow cytometric analysis
　Peripheral mononuclear blood cells （PMBCs） in phosphate-buffered saline （PBS） with 0.2％ 
（w / v） bovine serum albumin （BSA） were incubated on ice for 30 min with the following 
murine monoclonal antibodies against human antigens （50-fold dilutions）: Pacic Blue anti-CD3 
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（clone OKT3）, Brilliant Violet 510 anti-CD4 （clone OKT4）, PerPC / Cy5.5TM anti-CD45RA 
（clone HI100）, Alexa Fluor 488 anti-CCR7, PE / Cy7TM anti-CCR6 （clone G034E3）, and PETM 
anti-MCAM （clone P1H12）.  All anti-human protein antibodies used in ow cytometry were 
purchased from BioLegend （San Diego, CA, USA）.  Cells were washed twice with ice-cold PBS 
containing 0.2％ （w / v） BSA.  After ltration, cells were analyzed using a FACSAria II running 
the FACS Diva software （ver. 6.1 ; BD Biosciences, San Jose, CA, USA）.
　
Immunohistochemistry
　Immunohistochemical analysis was performed on 3 µm sections from formalin-fixed, paraffin 
wax-embedded specimens, using antibodies against the following proteins : CD3 （clone PS1, 
Novocastra, Newcastle, UK）, CD4 （clone 1F6, Novocastra）, CD8 （clone C8 / 144B, DakoCytoma-
tion A / S, Glostrup, Denmark）, CD146 / MCAM （clone EPR3028, Millipore Bedford, MA, USA）, 
CCR6 （clone 53103, R&D）, and IL-17 （polyclonal, goat ; LifeSpan Biosciences, Seattle, WA, USA）.
　
Evaluation of immune cells detected microscopically
　We determined the percentages of CCR6＋ cells in CD3＋ T cells, and the percentages of IL17＋ 
and MCAM＋ cells in 300 CD3＋ T cells in tissue sections （×400）.
　
Statistical analysis
　Paired or unpaired two-tailed Student’s t-tests were used to compare differences between 
groups.  A P-value of 0.05 was considered to indicate statistical signicance.  Spearman’s ordered 
correlation coefcients were calculated.
Results
The percentage of CCR6＋ MCAM＋ TEM cells paralleled the PASI score in psoriasis patients 
treated with biologics
　The PASI scores and percentages of CCR6＋ MCAM＋ TEM cells in seven psoriasis patients 
who were treated with biologics, such as iniximab, adalimumab, and ustekinumab （Table 1）, 
were monitored.  Six patients responded to the treatments and showed decreases in both PASI 
scores and percentages of CCR6＋ MCAM＋ TEM cells.  One patient （no. 5 in Table 1） was 
worse clinically after the treatments and the PASI scores and percentages of CCR6＋ MCAM＋ TEM 
cells were still increased.  Fig. 1 shows a typical case of parallel changes in PASI scores and per-
centages of CCR6＋ MCAM＋ TEM cells during treatment for psoriasis.  The patient was treated 
with iniximab and responded transiently, and then the treatment was changed to adalimumab. 
Subsequently, the symptoms improved.  Whether the shift was up or down, all changes in PASI 
score and the percentage of CCR6＋ MCAM＋ TEM were almost in parallel.  These results suggest 
that percentages of CCR6＋ MCAM＋ TEM in peripheral blood reected the therapeutic response.
Localization of T cells and expression of cellular markers in psoriasis and the examination of 
CCR6＋ MCAM＋ IL-17＋ cells by IF microscopy
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　In psoriatic lesional skin, most CD3＋ T cells （including CD4＋ cells and CD8＋ cells） were 
localized to certain regions of the upper dermis （Fig. 2a, b, c）; such accumulations of skin-
inltrating T cells are often observed in the perivascular areas of psoriatic lesional skin20）.  Large 
numbers of CCR6＋ cells as well as CD4＋ cells were present in the same area （Fig. 2d）, as well 
as some IL-17＋ cells and CCR6＋ cells （Fig. 2e, f）.
　We performed double staining to evaluate the consistency in numbers of CD4＋, CCR6＋ 
MCAM＋, IL-17＋ MCAM＋, and CCR6＋ IL-17＋ cells among patients and controls.  As shown 
in Fig. 2g, h, antibodies to MCAM （red） and IL-17 （green）, or antibodies to MCAM （green） 
and CCR6 （red）, stained CD4＋ cells in the upper dermis.  We concluded that the large 
MCAM＋ CD4＋ cells were not of the macrophage lineage, because they were negative for CD68 
（data not shown）, and cells of the myeloid lineage do not express MCAM15）.  These data sug-
gest that CCR6＋ MCAM＋ Th17 cells were present in the lesional skin of patients with psoriasis. 
Fig. 1.
0 
5 
10 
15 
20 
25 
30 
35 
0 50 100 150 200 250 300 350 400 450 500 550 600 
PASI CCR6+CD146+ 
PASI Infliximab 
Adalimumab 
CCR6+MCAM+ cells (%) 
Days 
Table 1．Changes in PASI scores and percentages of CCR6＋ MCAM＋ TEM in psoriatic patients 
　　　　 treated with biologics
　 PASI score ％ MCAM＋ CCR6＋ TEM
Patient Therapy before after before after
1 adalimumab（4 weeks） 20.9 4.8 7.7 0.6
2 adalimumab（14 weeks） 34.5 15.9 4.2 1.8
3 adalimumab （4 weeks） 26 5.4 8 1.5
4 ustekinumab（4 weeks） 14.3 8.1 4.7 2.1
5 ustekinumab（48 weeks） 5.8 15 3.3 7.5
6 iniximab （24 weeks） 13.5 0.8 6 2.8
7
infliximab （28 weeks） and 
adalimumab（30 weeks）
32 6 6.5 1.2
Seven patients were treated with biologics （adalimumab, ustekinumab, and/or iniximab） at Showa 
University Hospital.  Before, during, and after these treatments, PASI scores and ％ CCR6＋ 
MCAM＋ TEM were determined at least twice.
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Because CCR6 and MCAM are both involved in the migration of inammatory T cells14，18）, the 
elevated numbers of CCR6＋ MCAM＋ TEM cells in peripheral blood may migrate to lesional skin.
　
Correlations between IL-17＋ and MCAM＋ cell numbers in lesional skin and the severity of pso-
riasis
　We calculated the percentages of IL17＋ cells among 300 CD3＋ T cells evident in tissue sec-
tions, and compared these numbers to the disease severity in 34 psoriasis patients.  A signicant 
difference was evident between patients with mild （PASI＜ 12） and severe （PASI ≥ 12） disease 
（Fig. 3a）.  Moreover, we found a signicant correlation between the PASI score and IL17＋ cell 
numbers （r＝ 0.400 ; Fig. 3b）.  Next, we determined the proportions of MCAM＋ cells among 
CD3＋ cells in psoriatic lesional skin, and found signicantly higher proportions of MCAM＋ cells 
in the severe disease group than in patients with mild disease （Fig. 3c）.  There was also a mod-
erate and signicant correlation between the PASI score and MCAM＋ cell numbers （r＝ 0.42 ; 
Fig. 3d）.
Discussion
　A recent study found that the number of circulating MCAM＋ CD4 T cells was increased 
in patients with inammatory autoimmune diseases, including Behçet’s disease, sarcoidosis, and 
Fig. 3.
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Crohn’s disease, and that such numbers are correlated with disease severity21）.  Moreover, anti-
MCAM antibody therapy seemed to be potentially effective for the treatment of various Th17-
mediated diseases22）, suggesting that MCAM could play pathogenic roles in disease.  Indeed, the 
MCAM level in endothelial cells is increased by TNF, and it acts to enhance both angiogenesis 
and migration of activated monocytes into inamed tissues, suggesting that MCAM may augment 
the pathogenesis of psoriasis18）.  As shown in Table 1 and Fig. 1, the percentages of CCR6＋ 
MCAM＋ TEM cells in the blood reected the therapeutic response in parallel with PASI scores, 
supporting the notion of MCAM with a specic pathological role.  Thus, Th17 subtypes express-
ing MCAM might augment disease pathogenesis.  However, the number of patients tested in this 
study was low, and studies using more patient are needed.
　In this study, we showed that CCR6＋ MCAM＋ Th17 cells were present in psoriatic lesional 
skin and were more numerous in the peripheral blood of affected patients than in healthy con-
trols.  Although circulating Th17 cells can be recruited into lesional skin by CCR6 and MCAM, 
the source of the circulating Th17 cells remains unknown, and there are at least two possibilities. 
One is that inammatory dendritic cells in lesional skin migrate into lymph nodes and drive 
Th17 cells produced in the lymph nodes into the circulation.  Another is that Th17 cells pro-
duced by inammatory dendritic cells in lesional skin return to the circulation.  Because human 
adult naïve CD4 T cells have not been shown to develop into Th17 cells （unlike Th1 or Th2 
cells）23，24）, the latter possibility seems attractive.  However, the former one is supported by the 
observation that inammatory dendritic cells positive for IL-1β, IL-23, and CCR7 are present in 
psoriatic lesional skin （unpublished data）.
　In conclusion, we showed that CCR6＋ MCAM＋ TEM cells are enriched in the Th17 cells of 
peripheral blood of psoriasis patients, and that the numbers of CCR6＋ MCAM＋ Th17 cells in 
lesional skin may correlate with disease severity.  Moreover, the percentage of CCR6＋ MCAM＋ TEM 
cells in the blood of psoriasis patients reects the therapeutic response, and it could be a useful 
marker of the disease process.  Our results contribute to a better understanding of the relation-
ships between Th17 responses and the pathogenesis of psoriasis.
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